Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
DataMEDS AI (MEDS): A Closer Look at This Emerging Health IT Company

DataMEDS AI (MEDS): A Closer Look at This Emerging Health IT Company

Key Takeaways

  • MEDS represents the Nasdaq-listed common stock of DataMEDS AI, Inc., a small-cap health IT firm based in Tampa, Florida.
  • The company blends technology, pharmacy operations, pharmaceutical-related services, and telemedicine into one integrated healthcare platform.
  • Flagship offerings include EinsteinRx, an AI-driven pharmacy-dispensing system, and PharmacyChain, a blockchain-powered smart-contracts solution.
  • Beyond software, the business runs pharmacy distribution and clinical concierge services while advancing precision-medicine oncology tools via a subsidiary.
  • Previously known as Wellgistics Health, Inc., the firm rebranded to DataMEDS AI, Inc. in July 2026.

Introduction

MEDS serves as the ticker for DataMEDS AI, Inc., a healthcare technology company working to link the digital, pharmaceutical, and clinical elements of care within a single organization. I follow names like this because they sit at the crossroads of timely themes such as artificial intelligence, telemedicine, pharmacy innovation, and precision medicine, all within a relatively small, early-stage public entity.

Company Overview

DataMEDS AI positions itself as a health IT business centered on vertically integrating technology, pharmacy, pharmaceutical-adjacent activities, and telemedicine units. The aim is to create a smoother healthcare experience for patients by pairing software platforms with actual pharmacy operations.

Headquartered in Tampa, Florida, the shares trade on the Nasdaq Capital Market, a venue often linked to smaller and earlier-stage issuers. The company was incorporated in 2022 and operated as Wellgistics Health, Inc. until the July 2026 name change to DataMEDS AI, Inc.

Core Technology and Offerings

Its technology lineup focuses on several key platforms. EinsteinRx functions as an AI-powered pharmacy-dispensing tool, while PharmacyChain provides a blockchain-enabled smart-contracts system for pharmaceutical transactions. Additional components include the Patient Rx Adherence Tool to help with medication compliance and HubRx AI as part of broader hub and clinical-services technology.

Alongside these digital tools, the company maintains a pharmacy distribution operation and delivers clinical concierge services. A subsidiary is also developing precision-medicine oncology solutions intended to assist physicians and patients with complex cancer-care decisions.

Business Model

Operating as a holding company, DataMEDS AI oversees subsidiaries that handle wholesale and retail pharmaceutical products alongside technology and clinical services. The model mixes recurring software revenue with transaction-based pharmacy distribution, creating multiple potential income streams across the healthcare supply chain. This combination of technology and physical operations defines its vertical-integration approach.

Market Context

The company competes in a wide, fragmented healthcare-technology space that features established pharmacy distributors, telehealth providers, and health IT software firms. As a small-cap name, its position remains early-stage, with differentiation coming from the blend of AI and blockchain tools paired with hands-on pharmacy services rather than a narrow product focus.

Why Attention Turns to MEDS

Investor interest in MEDS largely reflects exposure to ongoing healthcare technology themes. The use of AI in pharmacy dispensing and clinical workflows matches industry efforts to boost efficiency and lower costs. Its precision-medicine and oncology work through a subsidiary aligns with expanding personalized cancer care.

The vertical-integration strategy, which pairs proprietary software with pharmacy distribution and clinical services, also stands out because it lets the business capture value at several points along the pharmaceutical journey. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. For those focused on small-cap and emerging health IT names, DataMEDS AI offers a single publicly traded vehicle for these themes.

Risks and Considerations

Like many small, early-stage healthcare companies, DataMEDS AI faces notable risks. Its financial profile shows continued investment in growth rather than consistent profitability, with net losses reported in recent periods. Limited size can constrain resources when competing against larger, better-funded players in pharmacy distribution and health IT.

Regulatory exposure is another factor, given that pharmaceutical distribution, telehealth, and clinical services fall under extensive U.S. healthcare rules. Reliance on newer technologies such as AI and blockchain means adoption and proven value at scale are still developing. Multiple name and strategic shifts in a short time add execution and brand challenges, and shares on the Nasdaq Capital Market can exhibit meaningful price swings.

Conclusion

DataMEDS AI remains an early-stage health IT company aiming to stand apart through the combination of AI and blockchain-enabled software with real-world pharmacy and clinical operations. Its vertical-integration model and developing precision-medicine efforts create a distinctive profile in the healthcare technology arena. For investors, MEDS provides a window into the convergence of artificial intelligence, pharmacy services, and personalized care—trends that continue to influence the wider healthcare sector.

Using AI Tools in My Research

When analyzing names like this, I often turn to Tickeron’s AI Screener to quickly filter opportunities across technical indicators, fundamentals, volatility, trends, and industry patterns. The platform lets me screen thousands of stocks and ETFs efficiently and surface ideas that align with specific strategies. It has become a regular part of my workflow for spotting comparable names or validating themes in health IT.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MEDS

MEDS in downward trend: price dove below 50-day moving average on October 22, 2026

MEDS moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 27 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for MEDS crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for MEDS entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDS advanced for three days, in 138 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

MEDS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.423). P/E Ratio (0.000) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (4.260).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MEDS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MEDS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 23.75B. The market cap for tickers in the group ranges from 44.8K to 123.68B. MCK holds the highest valuation in this group at 123.68B. The lowest valued company is COCM at 44.8K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was -13%. For the same Industry, the average monthly price growth was -25%, and the average quarterly price growth was -28%. MCK experienced the highest price growth at 0%, while ACH experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was 60%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 48
Price Growth Rating: 61
SMR Rating: 88
Profit Risk Rating: 73
Seasonality Score: -2 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalDistributors

Industry
N/A
Address
2420 Brunello Trace.
Phone
+1 800 261-0281
Employees
34
Web
https://www.rx.trxade.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.